Alopexx Enterprises works with scientists and entrepreneurs to build successful new companies. We invest in novel health care technologies at all stages of development and can serve as a lead investor or collaborate with a group of investors to advance important science. We also have the capabilities to provide management and development expertise where needed. To date, our initial investments have ranged from $1-20M.
The Alopexx team consists of experts who have deep industry knowledge and technical expertise in all areas of drug development including, pharmacology, CMC, toxicology, medical and clinical operations, quality and regulatory affairs. We form collaborations with academic institutions, biotech and pharmaceutical companies to advance our portfolio companies to deliver breakthrough therapies to patients in need.
Our business model is to invest and develop to an important inflection point and then partner the asset for further development and/or commercialization.
Many factors enter into our investment decisions, but three elements should be present:
- Sound science behind novel technology
- Products that can be differentiated in the marketplace
- Solid IP protection
Alopexx Enterprises, LLC is funded by the Pritzker/Vlock family office and associated trusts. The Pritzker/Vlock family office is managed by Karen Pritzker and Michael Vlock. This enterprise owns and manages a broad portfolio of public equities, consumer, biotech, industrial, medical equipment and technology businesses, several seed capital and venture funds, and real estate.